Dossier
clinicaltrials
trial early
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Key claim: Bezuclastinib (CGT9486) is being evaluated in an open-label two-part Phase 2 study for advanced systemic mastocytosis, including ASM, SM-AHN, and mast cell leukemia.
Abstract
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Why this matters
Bezuclastinib (CGT9486) is being evaluated in an open-label two-part Phase 2 study for advanced systemic mastocytosis, including ASM, SM-AHN, and mast cell leukemia.